Viruses · 2020 · 66 citations · 57 references
MedicineInfectious DiseasesPharmacologyDrug DiscoveryMolecular VirologyVirologyAntiviral AgentsAntiviral ImmunityAntiviral PharmacologyAntiviral PharmacotherapyAntiviral TherapyAntiviral TherapeuticsAntiviral TreatmentDihydroorotate Dehydrogenase InhibitorsHost-targeted AntiviralsPotency AssaysSars-cov-2 Antiviral TherapySars-cov-2 InfectionWestern Blot Analysis
The ongoing pandemic spread of the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) demands skillful strategies for novel drug development, drug repurposing and cotreatments, in particular focusing on existing candidates of host-directed antivirals (HDAs). The developmental drug IMU-838, currently being investigated in a phase 2b trial in patients suffering from autoimmune diseases, represents an inhibitor of human dihydroorotate dehydrogenase (DHODH) with a recently proven antiviral activity in vitro and in vivo. Here, we established an analysis system for assessing the antiviral potency of IMU-838 and DHODH-directed back-up drugs in cultured cell-based infection models. By the use of SARS-CoV-2-specific immunofluorescence, Western blot, in-cell ELISA, viral yield reduction and RT-qPCR methods, we demonstrated the following: (i) IMU-838 and back-ups show anti-SARS-CoV-2 activity at several levels of viral replication, i.e., protein production, double-strand RNA synthesis, and release of infectious virus; (ii) antiviral efficacy in Vero cells was demonstrated in a micromolar range (IMU-838 half-maximal effective concentration, EC50, of 7.6 ± 5.8 µM); (iii) anti-SARS-CoV-2 activity was distinct from cytotoxic effects (half-cytotoxic concentration, CC50, >100 µM); (iv) the drug in vitro potency was confirmed using several Vero lineages and human cells; (v) combination with remdesivir showed enhanced anti-SARS-CoV-2 activity; (vi) vidofludimus, the active determinant of IMU-838, exerted a broad-spectrum activity against a selection of major human pathogenic viruses. These findings strongly suggest that developmental DHODH inhibitors represent promising candidates for use as anti-SARS-CoV-2 therapeutics.
57
Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
Victor M. Corman, Olfert Landt, Marco Kaiser et al. · Eurosurveillance · 2020 · 8.2K citations · Full text
Neutrophil extracellular traps in COVID-19
Yu Zuo, Srilakshmi Yalavarthi, Hui Shi et al. · JCI Insight · 2020 · 1.6K citations · Full text